Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Imaging Core Lab LLC

Neither a doctor nor a teaching hospital

Research payments

$911,872

70 payments

Through program year 2025, Boston Imaging Core Lab LLC is reported as receiving $911,872 in research payments, across 70 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $6,775 1
2024 Research $1,815 1
2023 Research $703,612 62
2021 Research $32,800 1
2020 Research $69,950 2
2019 Research $96,920 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. GRT US Holding, Inc. $698,062 60 payments
  2. E.R. Squibb & Sons, L.L.C. $208,260 8 payments
  3. Pfizer Inc. $5,550 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Singlearm Openlabel Phase III Trial to Evaluate the Safety and Tolerability of Intraarticular Injections of Rtxgrt7039 in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee $324,814 20 payments
  2. A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma $199,670 6 payments
  3. A Randomized Doubleblind Placebocontrolled Phase III Trial to Evaluate the Efficacy and Safety of A Single Intraarticular Injection of Rtxgrt7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee $197,715 20 payments
  4. A Randomized Doubleblind Placebocontrolled Phase III Trial to Evaluate the Efficacy and Safety of Intraarticular Injections of Rtxgrt7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee $175,533 20 payments
  5. A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) $6,775 1 payment
  6. Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib Ibranceregistered in Combination With Irinotecan and Temozolomide and in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent Or Refractory Solid Tumors $5,550 2 payments
  7. A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-nave ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) $1,815 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record